News | May 02, 2026
FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
After Phase 3 results show major hair regrowth gains
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Subscribe To Our Newsletter & Stay Updated
